ALLR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Allarity Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $11.81 Mil. Allarity Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $22.65 Mil.
The historical rank and industry rank for Allarity Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 6 years, the highest Equity to Asset Ratio of Allarity Therapeutics was 0.73. The lowest was -0.23. And the median was 0.45.
The historical data trend for Allarity Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allarity Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.73 | 0.38 | 0.13 | -0.23 | 0.52 |
Allarity Therapeutics Quarterly Data | |||||||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.23 | -0.54 | 0.64 | 0.64 | 0.52 |
For the Biotechnology subindustry, Allarity Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Allarity Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Equity to Asset (A: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 11.811 | / | 22.65 | |
= |
Allarity Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
Equity to Asset (Q: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 11.811 | / | 22.65 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allarity Therapeutics (NAS:ALLR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Allarity Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura Benjamin | director | 168 GOODRICH ST., LUNENBURG MA 01462 |
Joseph Walter Vazzano | director | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Gerald W. Mclaughlin | director | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
David Roth | director | C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Joan Yvonne Brown | officer: Chief Financial Officer | C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434 |
Steve Carchedi | director, officer: Chief Executive Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Steen Knudsen | officer: Chief Scientific Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Jens Erik Knudsen | officer: Chief Financial Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Soren Gade Jensen | director | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Duncan Moore | director | C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432 |
Thomas Jensen | officer: SVP, Information Technology | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
James G. Cullem | officer: SVP, Chief Business Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Marie Foegh | officer: Chief Medical Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Sass & Larsen Aps | 10 percent owner | VESTERGARDSVEJ 6, GREVE G7 DK-2670 |
Leon Sass | 10 percent owner | JERNBAEK ALLE 5, HELSINGE G7 DK-3200 |
From GuruFocus
By Business Wire • 11-12-2024
By Marketwired • 11-14-2024
By Marketwired • 11-04-2024
By Marketwired • 11-12-2024
By Marketwired • 02-24-2025
By PRNewswire • 11-08-2024
By Marketwired • 12-06-2024
By Business Wire • 11-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.